|Dr. Alexander D. Macrae||CEO, Pres & Director||1.2M||N/A||1963|
|Mr. Gary H. Loeb||Exec. VP, Gen. Counsel, Chief Compliance Office & Sec.||612.2k||N/A||1970|
|Dr. R. Andrew Ramelmeier Ph.D.||Exec. VP of Technical Operations||675.48k||N/A||1962|
|Mr. D. Mark McClung||Exec. VP & Chief Bus. Officer||568k||N/A||1963|
|Ms. Prathyusha Duraibabu CPA, M.B.A.||Sr. VP & CFO||N/A||N/A||1979|
|Dr. Jason D. Fontenot Ph.D.||Sr. VP & Chief Scientific Officer||N/A||N/A||1970|
|Ms. Aron Feingold||Head of Corp. Communications & Investor Relations Officer||N/A||N/A||N/A|
|Ms. Whitney Jones||Sr. VP & Chief People Officer||N/A||N/A||N/A|
|Dr. Nathalie Dubois-Stringfellow||Sr. VP of Product Devel. & Management||N/A||N/A||N/A|
|Ms. Heather Erickson||Chief of Staff||N/A||N/A||N/A|
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.
Sangamo Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 3. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 2; Compensation: 6.